Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor with Azacitidine and Venetoclax (SAV) for Untreated AML
NCT05736965Phase 2Recruiting
- Sponsor
- Shanghai Tongren Hospital
- Start
- Feb 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in acute myeloid leukemia (AML), sponsored by Shanghai Tongren Hospital. Started Feb 2023; status: recruiting.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05736965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05736965.